Cargando…

Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation

BACKGROUND: Breast cancer (BC) is a leading cause of premature death in women and the most expensive malignancy to treat. Since the introduction of targeted therapies has resulted in changes to BC therapy practices, health economic evaluations have become more important in this area. Taking generic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Althuwaibi, Maha F., Fernandez-Garcia, Cristina, Hayes, Louise, McNally, Richard, Coughlan, Diarmuid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294338/ https://www.ncbi.nlm.nih.gov/pubmed/37365615 http://dx.doi.org/10.1186/s12913-023-09432-5

Ejemplares similares

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice
por: Hirakawa, Hachidai, et al.
Publicado: (2014)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer
por: Lu, Qianyi, et al.
Publicado: (2019)

Cannabidiol as a Promising Adjuvant Therapy for Estrogen Receptor-Positive Breast Tumors: Unveiling Its Benefits with Aromatase Inhibitors
por: Almeida, Cristina Ferreira, et al.
Publicado: (2023)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
por: Najjar, Omar, et al.
Publicado: (2020)

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
por: Miller, Christopher A., et al.
Publicado: (2016)

Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report
por: Liang, Angela L., et al.
Publicado: (2021)

Aromatase Expression Increases the Survival and Malignancy of Estrogen Receptor Positive Breast Cancer Cells
por: Mukhopadhyay, Keya De, et al.
Publicado: (2015)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Salivary Estrogens Androgens and Aromatase Inhibitors by LC-MS/MS in Breast Cancer Patients Treated With Testosterone Pellets Combined With Aromatase Inhibitors
por: Zava, David T, et al.
Publicado: (2021)

p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors
por: Yamamoto, Mitsugu, et al.
Publicado: (2014)

Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
por: Lui, Asona, et al.
Publicado: (2016)

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
por: Kim, Wonjin, et al.
Publicado: (2015)

Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
por: Sabale, Ugne, et al.
Publicado: (2017)

Design, Synthesis and Biological Evaluation of Aromatase Inhibitors Based on Sulfonates and Sulfonamides of Resveratrol
por: Fantacuzzi, Marialuigia, et al.
Publicado: (2021)

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors
por: Thanopoulou, Eirini, et al.
Publicado: (2014)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

Molecular Basis for Endocrine Disruption by Pesticides Targeting Aromatase and Estrogen Receptor
por: Zhang, Chao, et al.
Publicado: (2020)

The Aromatase–Estrogen System in the Testes of Non-Mammalian Vertebrates
por: Rosati, Luigi, et al.
Publicado: (2021)

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
por: Zilembo, N., et al.
Publicado: (1995)

Phosphorylation of the Mutant K303R Estrogen Receptor α at Serine 305 Impacts Aromatase Inhibitor Sensitivity
por: Barone, Ines, et al.
Publicado: (2010)

Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer
por: El-Kersh, Dina M., et al.
Publicado: (2021)

Expression of Estrogen-Related Gene Markers in Breast Cancer Tissue Predicts Aromatase Inhibitor Responsiveness
por: Moy, Irene, et al.
Publicado: (2013)

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
por: Reinert, Tomás, et al.
Publicado: (2020)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome
por: Grindstad, Thea, et al.
Publicado: (2016)

Assessment of Five Pesticides as Endocrine-Disrupting Chemicals: Effects on Estrogen Receptors and Aromatase
por: Gea, Marta, et al.
Publicado: (2022)

An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER(+)) Breast Cancer: Effects on Sensitive and Resistant Cell Lines
por: Amaral, Cristina, et al.
Publicado: (2023)

Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo
por: Meijer, Danielle, et al.
Publicado: (2011)

Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs)
por: Schiff, Rachel, et al.
Publicado: (2003)

Aromatase expression and role of estrogens in male gonad : a review
por: Carreau, Serge, et al.
Publicado: (2003)

Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas
por: Crowley, Fionnuala, et al.
Publicado: (2022)

Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment
por: Takagi, K, et al.
Publicado: (2013)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Aromatase inhibitors in male sex
por: Singh, Santosh Kumar
Publicado: (2013)

Aromatase inhibitors in the treatment of endometriosis
por: Słopień, Radosław, et al.
Publicado: (2016)

Molecular Docking of Aromatase Inhibitors
por: Suvannang, Naravut, et al.
Publicado: (2011)

Aromatase Inhibitors in Erectile Dysfunction
por: Singh, Santosh
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7mpq8j5jt90am7hjhbfn8q22f4